2025 年 66 巻 4 号 p. 699-705
Heart failure (HF) is one of the most common cardiovascular diseases in the 21st century, affecting more than 25 million individuals worldwide. According to estimates, 8.9 million cases have been reported in China alone. Although pharmacotherapy remains an integral part of the treatment of HF, even with optimized medical treatment, many patients continue to experience symptoms and frequent rehospitalizations with a poor prognosis. This case series assessed the possible benefits of a left ventricular cardiac contractility modulation (CCM) device in 5 patients with chronic HF who had poor outcomes with medication alone. This study aimed to establish improvements caused by CCM in cardiac function and quality of life by analyzing variations in echocardiographic parameters, myocardial biomarkers, and exercise tolerance. Follow-ups at 1 and 6 months postoperatively showed equally impressive improvements in cardiac function, with equally dramatic improvements in quality of life.
